FDA Approves First Weekly Injectable Suspension Type 2 Diabetes Treatment in Certain Pediatric Populations

July 23, 2021

A once-weekly injectable suspension has been approved in the U.S. for the treatment of type 2 diabetes. Marketed by AstraZeneca as BYDUREON BCise (exenatide extended-release), it has been shown to to improve glycemic control in pediatric patients (10 to 17 years) as an adjunct to diet and exercise. The approval by the US Food and […]

To view the full Member Resource, please Log in

TOPICS IN THIS ARTICLE:

Diabetes News and Research Pediatric Health

Join the Global Movement Advancing Endocrine Science and Medicine

Become a part of a community of 18,000-plus endocrine investigators and clinicians who conduct research and provide quality patient care in more than 100 countries. Advance your career and the field of endocrinology through our many educational, leadership and advocacy opportunities.

Join Today

RELATED ARTICLES

Heroin Adulterated with Diabetes Medication Triggers Life-Threatening Medical Emergencies

Hyperinsulinemia Emerges as Critical Predictor of Severe Liver Outcomes

Father’s Tobacco Use May Raise Children’s Diabetes Risk

Health Topics

Patient Populations